PRECISION ONCOLOGY CYCLE

ABOUT US

 

Over the past couple of decades, the exponential progress of sequencing technologies has allowed an increasing number of cancer patients to benefit from precision oncology. However, the aggregation, analysis, and visualization of the massive amounts of genomic data remain a major challenge for precision oncology expansion.

The Epigene Labs technology platform enables cancer drug hunters to seamlessly leverage advanced artificial intelligence in transforming genomic data into actionable insights for designing precision oncology approaches.

With R&D in Paris and business development in Boston, Epigene Labs operates in the setting of value-based partnerships with world leading cancer centers and high-profile biotechs.

 
 

OUR TEAM

We are humble. We are bold.

 

OUR SCIENTIFIC ADVISORY BOARD

 
Chloé-Agathe Azencott, PhD

MINES PARISTECH PARIS

Dominique Bellet, PharmD, MD, PhD

UNIVERSITY OF PARIS PARIS

Jean-François Zagury, MD, PhD

CNAM PARIS

Martin Aryee, PhD

MGH-HARVARD BOSTON

 
 

SUPPORTERS

They trust us

  • iTeos Therapeutics

  • AstraZeneca

  • UCSF

  • Institut Curie

  • Harvard Innovation Labs

  • Daphni

  • Station F

  • WILCO
 
 

GET IN TOUCH

 

Interested in partnering or working with us? Drop us a line!